Company History

2024 / 12: MegaPro new MRI contrast agent MPB-2043 has completed the first patient admission in Taiwan.
2024 / 10: MegaPro new drug MPB-2354 issues a press release on WMIS.
2024 / 10: MegaPro MPB-1734 completes the phase 1 of the last patient, press release.
2024 / 04: MegaPro MPB-1734 Receives Composition of Matter Patents in the U.S. and Japan.
2023 / 02: MegaPro MPB-1523 clinical phase II trial results were published in international journals.
2021 / 10: MegaPro Biomedical held an investor’s conference on the 14th before the release of emerging stocks.
2021 / 08: Completed series D of cash capital increase.
2021 / 04: MegaPro Biomedical's new drug MPB-1734 new dosage form anticancer drug has passed the application of Taiwan TFDA 1/2a clinical trial case.
2021 / 02: The company's new drug MPB-1734, a new anticancer drug, has submitted a 1/2a trial application to the Taiwan Ministry of Health and Welfare (TFDA).
2021 / 01: MegaPro Biomedical became a public company (stock code: 6827).
2020 / 12: Re-approved by the Ministry of Economic Affairs as a biotechnology new drug company.
2020 / 11: MegaPro Biomedical's new drug MPB-1734 new dosage form anticancer drug has passed the US FDA clinical I/IIa IND application.
2019 / 12: Completed series C+ of cash capital increase.
2019 / 11: MegaPro Biomedical participated in the Contrast Media Research (CMR) 2019 seminar in Italy to promote the company's MPB-1523 product, and was invited to give a speech on “Superparamagnetic iron oxide nanoparticles modified with polyethylene glycol (MPB-1523) in clinical MRI imaging diagnosis of stage II liver cancer patients.”
2018 / 11: Won the "15th National Innovation Award-Enterprise Innovation Award".
2018 / 07: Won the 2018 Taipei Biotechnology Award - New Technology Award / Silver Award.
2018 / 06: Completed C round of capital increase.
2018 / 05: MegaPro Biomedical's new drug IOP injection-MPB-1514 was notified by the US FDA to carry out Phase II clinical trials.
2018 / 04: The Phase 2 clinical trial of MegaPro Biomedical's new drug IOP injection-MPB-1514 has been submitted to the US FDA for review.
2018 / 04: Completed Phase 1b clinical trial of IOP injection-MPB-1523 at Taipei Veterans General Hospital.
2018 / 02: MegaPro Biomedical's new drug IOP injection-MPB-1523 was notified by the Taiwan TFDA of its approval for the implementation of clinical phase 2 trials.
2018 / 01: MegaPro Biomedical's new drug IOP injection-MPB-1523 was notified by the US FDA of its approval to carry out clinical phase 2 trials.
2017 / 12: MegaPro Biomedical's new drug IOP injection-MPB-1523 was notified by the Taiwan TFDA to be approved for the clinical Phase 1b trial.
2017 / 08: Hsinchu Science Park Bureau has approved the company to settle into the science park.
2017 / 06: Completed the IOP injection-MPB-1523 clinical phase 1 clinical trial closing report.
2016 / 12: Completed Phase I trial of IOP injection-MPB-1523 at Taipei Veterans General Hospital.
2016 / 12: Wins the 13th National Startup Award-Startup Enterprise Award.
2016 / 10: Completed B round of capital increase.
2016 / 03: The Phase I trial of IOP injection-MPB-1514 was launched at Taipei Veterans General Hospital.
2016 / 03: IOP injection was awarded the project subsidy of the A+ Enterprise Innovation R&D Chain Quenching Program-Fast Review Clinical Trial Program (Fast track) project of the Ministry of Economic Affairs' Science and Technology Research and Development Project.
2016 / 02: The Phase I trial of IOP injection-MPB-1523 was launched at Taipei Veterans General Hospital.
2016 / 02: Approved by the Ministry of Economic Affairs as a new biotechnology company.
2016 / 01: Selected as an index case by the Taiwan Pharmaceutical Inspection Center (CDE).
2015 / 12: MegaPro Biomedical's research and development of a new Chinese medicine MPB-1523 was notified by Taiwan's TFDA of its approval the implementation of Phase I clinical trial (Phase I).
2015 / 08: To process and file for changes in the company business operations, including Western medicine wholesale, Western medicine retail, medical equipment wholesale, medical equipment retail, and drug inspection.
2015 / 08: Finalist of Rookie Award for Biomedical Agronomy Draft Contest.
2015 / 01: Complete round A of capital increase.
2015 / 01: The company team is a spin-off by the Industrial Research Institute.
2014 / 11: Founded.